With legislation to expand health care coverage pending in the US Congress, the question of comparative costs and benefits of various therapies is an issue of vital interest. Because costs of cancer treatments are even at present very high and are projected to increase with an aging population, the costeffectiveness of specific cancer therapies represents an urgent national concern. Integrative approaches to cancer are certainly not exempt from questions of cost-effectiveness. So it is fair to ask what research is there to demonstrate cost-effectiveness of integrative cancer therapies.
Editorial
With legislation to expand health care coverage pending in the US Congress, the question of comparative costs and benefits of various therapies is an issue of vital interest. Because costs of cancer treatments are even at present very high and are projected to increase with an aging population, the costeffectiveness of specific cancer therapies represents an urgent national concern. Integrative approaches to cancer are certainly not exempt from questions of cost-effectiveness. So it is fair to ask what research is there to demonstrate cost-effectiveness of integrative cancer therapies.
Of course, it is necessary before assessing cost-effectiveness to assess the clinical effectiveness of treatment. We should be mindful that there is still much work to be done in determining whether-or which-integrative treatments are clinically effective while keeping in mind that treatment tolerance and quality of life affect outcome. Questions of cost-effectiveness also need systematic assessment of economic outcomes. Herman et al, 1 for instance, found in a 2005 review that a variety of complementary and alternative medicine (CAM) therapies including acupuncture, stress management, diet, and omega-3 fatty acid supplements have gone through formal economic evaluations. In general, the health effects of the CAM therapies were better than the conventional alternatives tested. Half of the CAM therapies had lower costs than conventional therapies, whereas the other half had similar or higher costs. Specifically for cancer, one study found that a self-administered stress management program was more cost-effective than a professionally administered stress management program in reducing stress for cancer patients undergoing chemotherapy. It was also the case that the self-administered stress management program had a better outcome. We would note that this particular finding will not necessarily apply to all types of stress management programs, many of which may well be more effective when administered by professionals. If research is to be done on an integrative intervention that may add costs, it should initially be shown to have better outcomes or at least improve life quality more effectively than conventional care alone before attempting a cost-effectiveness analysis.
As Herman et al 1 point out, there are a variety of measurements for cost-effectiveness. These include cost-benefit analysis; cost-utility analysis, which uses the concept of quality-adjusted years of life; cost-minimization analysis; and cost-identification studies. Each of these has different features and is useful for different situations. Sagar 2 points out that these studies, which typically analyze specific and relatively short-term interventions, may not be entirely suitable for integrative medicine because of their restricted time frame. Integrative strategies used over the long term may turn out to be more cost-effective than any short-term, less expensive interventions. Such treatments do not address a patient's overall health and do not teach effective self-care, which is fundamental to integrative methods.
The literature on cost-effectiveness of integrative cancer interventions is certainly limited, but it is instructive to review some examples of relevant studies to make at least an attempt at responding to the important questions of health care costs in our current political situation. I include in this group of studies interventions that have been shown to reduce days of hospitalization, reduce treatment side effects and symptoms, or similar variables that translate rather directly into costs. The costs of the integrative interventions themselves are, in general, relatively small. The areas in which relevant studies can be found include mind-body interventions, supplements, and exercise.
Astin et al 3 reviewed the effectiveness of mind-body medicine for a variety of health outcomes in 2003. They found strong evidence from 2 meta-analyses that cancer symptoms were effectively controlled by mind-body interventions such as relaxation, hypnosis, and support groups. These interventions were found to have efficacy in coping with both disease symptoms and treatment-related side effects, such as acute pain associated with diagnostic and treatment procedures and anticipatory nausea and vomiting. Strong evidence was also found for effects of mind-body therapies (relaxation, guided imagery, hypnosis, and instructional interventions) as part of surgical preparation, including reducing pain, medication use, and recovery time. One review of 76 studies mentioned by Astin et al found that hospital stays were reduced by an average of 1.5 days for patients receiving mind-body therapies. Among studies that have specific economic analyses, a presurgery relaxation tape was found to reduce length of stay by 1.6 days for colon surgery patients, at a cost savings of $3200. A randomized study of hypnosis used as an adjunct to sedation during outpatient interventional radiology procedures included patients undergoing nephrostomy as well as patients undergoing other renal and cardiovascular procedures. 4 In this study, patients either underwent standard sedation or sedation with adjunct hypnosis. A thorough economic analysis was performed in 79 cases with respect to cost of the hypnosis provider, cost of room time for radiology, hours of observation after the procedure, and frequency and cost of complications associated with oversedation or undersedation. Overall, the cost of a standard sedation procedure was $638, compared with a cost of $300 per patient for those who had adjunct hypnosis. Reduced room time was a major element in the cost reduction. Additionally, 20% of standard sedation patients were oversedated, whereas only 11% of hypnosis patients showed such problems. Also, 30% of standard sedation patients were undersedated as against only 10% of hypnosis patients. With the importance of surgery and radiation in cancer treatment and the need for effective and costeffective control of symptoms and side effects, a systematic approach to incorporating mind-body therapies offers substantial promise in reducing medical costs as well as in improving health.
Dietary supplements also contribute to improving tolerance of treatments. A randomized trial of parenteral nutrition for bone marrow transplant patients focused on a commonly used integrative nutraceutical supplement, glutamine, introduced among some of our integrative clinics much before it began making its way in mainstream centers. Glutaminesupplemented versus isonitrogenous nonglutamine formula was tested in a 1994 study. 5 Length of hospitalization was significantly shorter in the glutamine-supplemented group (29 days versus 36 days), and clinical infections and positive microbial cultures were also fewer. Overall, hospitalization charges were $21 095 less in the glutamine-supplemented patients. Room and board charges, specifically, were $51 484 for the glutamine group and $61 591 for the control group. This is certainly a significant cost savings. Glutamine, therefore, merits further investigation for mitigation of numerous side effects of chemotherapy treatment. Not implementing such a therapy with these profound clinical and cost-saving benefits in the conventional arena leaves patients unnecessarily vulnerable and compromised. Yet this important integrative oncology therapy is still rarely included in oncology protocols in most institutional centers. Additionally, a randomized study of cancer chemotherapy and radiotherapy patients who received pycnogenol or placebo found that only 2.9% of radiotherapy pycnogenol patients developed venous thrombosis, whereas 10% of control patients developed it; among chemotherapy patients, 4% of pycnogenol versus 19% of control patients developed thrombosis. Fewer days of hospitalization and lower medical costs were also recorded for the pycnogenol groups. 6 And, certainly, the finding presented at this year's ASCO meeting that a daily dose of as little as half a gram of ginger decreased nausea in chemotherapy patients receiving antiemetic drugs indicates a potential cost savings in possible dose reduction of more expensive antiemetic/antinausea drugs for patients who take an inexpensive and widely available herb. 7 Additionally, psychooncology trials have indicated that progressive muscle relaxation combined with relaxed focused imagery can help reduce or eliminate nausea/vomiting when antiemetic drugs by themselves are insufficient for chemotherapy patients. 8, 9 Finally, the effect of exercise on performance, treatment side effects, and hospitalization was studied by Dimeo et al 10 in cancer patients receiving high-dose chemotherapy and stem cell transplants. Patients in the treatment group exercised on recumbent ergometers, whereas the control group did not exercise. The exercising patients had significantly shorter duration of neutropenia and thrombopenia, and less diarrhea and pain than the control patients-all complications that need drug treatment and thus imply additional medical costs. Hospitalization was somewhat more than a day less in the exercise group than in the control group.
Integrative cancer interventions are rapidly moving toward acceptance as routine components of our existing health care system. Although more evidence is needed to confirm this approach as a means to effect cost savings, preliminary indications are that introducing these strategies could be among the major solutions needed. This brief review of clinically and economically significant findings suggests that further careful work in this area is certainly merited. The extent to which integrative care will eventually be included in health care coverage is still unclear. What is clear, though, is that many patients value what they receive from integrative interventions enough to pay for it out of pocket. The value perceived by patients is not always easy to capture in randomized trials. But it is easy to conclude that we need to continue to explore the clinical effectiveness-in all clinically relevant dimensions for patients-of integrative care as a basis for eventual cost decisions.
Beyond the obvious benefits of breathing life into a submerged medical system weighted by high costs, with limited time for care and limited strategies to help patients maintain quality of life while combating malignant disease, therapies that allow patients to maintain chemotherapy dosing, avoid delays or interruption in their drug schedule, or reduce the risk of premature abandonment of treatment are likely to improve patients' outcomes-truly the chief aim of every health professional.
